About: Advances in the possible treatment of COVID-19: A review.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Advances in the possible treatment of COVID-19: A review. Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Advances in the possible treatment of COVID-19: A review.
Creator	Ahmed, Irfan Haq, Syed Andrabi, Iqbal Chibber, Pankaj Singh, Gurdarshan
Source	Elsevier; Medline; PMC
abstract	The emergence of the global pandemic caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has put a challenge to identify or derive the therapeutics for its prevention and treatment. Despite the unprecedented advances in the modern medicinal system, currently, there are no proven effective therapies. However, rapid research on SARS-CoV-2 epidemiology help unveiling some new targets for potential drug therapies. Many drugs have been screened, and even their clinical trials are going on at an exceptional pace. Amongst these RNA-dependent RNA polymerase inhibitors (favipiravir and remdesivir) and steroids especially dexamethasone showed promising effects. The biological agents like tocilizumab, interferons, and convalescent plasma prove to be beneficial in viral clearance. Moreover, many immunomodulatory and viral S protein targeting vaccines have their ongoing clinical trials. The establishment of various in vitro and in vivo models for preclinical studies can additionally help the current research. The volume and the pace of the clinical trials launched to evaluate the safety and efficacy of various agents against coronavirus disease 2019 (COVID-19) reflect the need for high-quality evidence for various therapies to be practiced by clinicians. This study aims to sum up all the current advances in the global medicinal system against the COVID-19.
has issue date	2020-09-15(xsd:dateTime)
bibo:doi	10.1016/j.ejphar.2020.173372
bibo:pmid	32682787
has license	no-cc
sha1sum (hex)	608293ddfe8728309fe6b7bc6a4b5b9801e78a9c
schema:url	https://doi.org/10.1016/j.ejphar.2020.173372
resource representing a document's title	Advances in the possible treatment of COVID-19: A review.
has PubMed Central identifier	PMC7366101
has PubMed identifier	32682787
schema:publication	Eur J Pharmacol
resource representing a document's body	covid:608293ddfe8728309fe6b7bc6a4b5b9801e78a9c#body_text
is schema:about of	named entity 'immunomodulatory' named entity 'screened' named entity 'coronavirus disease 2019' named entity 'SARS-CoV-2' named entity 'system' named entity 'proven' named entity 'promising' named entity 'potential' named entity 'medicinal' named entity 'viral' named entity 'preclinical studies' named entity 'clinicians' named entity 'tocilizumab' named entity 'COVID-19' named entity 'biological agents' named entity 'epidemiology' named entity 'COVID' named entity 'vaccines' named entity 'tocilizumab' named entity 'convalescent plasma' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'remdesivir' named entity 'favipiravir' named entity 'COVID-19' named entity 'global' named entity 'proofreading' named entity 'SARS-CoV-2' named entity 'ARDS' named entity 'SARS-CoV-2 virus' named entity 'arbidol' named entity 'immunomodulatory' named entity 'chloroquine' named entity 'medical products' named entity 'clinical trials' named entity 'viruses' named entity 'IFN' named entity 'approved drug' named entity 'RNA synthesis' named entity 'infection' named entity 'CD11c' named entity 'hydroxychloroquine' named entity 'COVID-19' named entity 'hydroxychloroquine' named entity 'viruses' named entity 'preventive measures' named entity 'IL-6' named entity 'protease' named entity 'tocilizumab' named entity 'plasma' named entity 'favipiravir' named entity 'immunomodulatory' named entity 'remdesivir' named entity 'SARS-CoV-2' named entity 'death rate' named entity 'infection' named entity 'SARS outbreak' named entity 'remdesivir' named entity 'HKU1' named entity 'antibacterial' named entity 'Vero E6' named entity '13.5' named entity 'lopinavir/ritonavir' named entity 'AAK1' named entity 'SARS-CoV' named entity 'Azithromycin' named entity 'cytokines' named entity 'adenosine' named entity 'SARS-CoV' named entity 'State Administration of Traditional Chinese Medicine' named entity 'ribavirin' named entity 'mice' named entity 'receptor-mediated endocytosis' named entity 'COVID' named entity 'chloroquine' named entity 'baricitinib' named entity 'TMPRSS2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software